Thaddeus Stappenbeck, MD, PhD
Insurance
Is Cleveland Clinic Part of Your Insurance?
Review a list of accepted insurance plans for our Northeast Ohio locations or learn more about purchasing a contracted managed care plan.
View All PlansAbout Thaddeus Stappenbeck, MD, PhD
Thaddeus Stappenbeck received his B.A. as a member of the Integrated Science Program at Northwestern University, as well as his M.D and Ph.D. from Northwestern University Medical School. He trained in anatomic pathology at the Washington University School of Medicine. He was hired as an assistant Professor in the Department of Pathology and Immunology at Washington University, where he moved up the ranks to Division Chief of Laboratory and Genomic Medicine. His leadership experiences included lead of the Physician Scientist Training Program, Pathology and Immunology promotions committee chair, study section chair and multiple search committees for leadership positions.
Dr. Stappenbeck currently serves as the chair of Inflammation and Immunity at Cleveland Clinic, where his research program focuses on determining the root causes of inflammatory and infectious diseases with the goal of developing new therapies for these diseases. His lab has defined stages and mechanisms of intestinal repair leading to a lead compound for a novel therapy for inflammatory bowel disease and idiopathic pulmonary fibrosis, determined mechanisms for the effects of intestinal microbes on repair and created a cell culture system for human intestinal stem cells that is used by labs around the world. He moved to Cleveland Clinic to partner with the world-class clinicians and scientists in this institution to accelerate the translation of discoveries in immunology, developmental biology, cell biology, and microbiology to new concepts for therapy in inflammatory disease.
He serves on scientific advisory boards for Science Immunology, as well as several companies in the area of inflammatory bowel diseases. He has collaborated extensively with many other investigators and published over 160 articles in high impact journals, while successfully training numerous physician-scientists and scientists and encouraging them to inflammatory and infectious disease. His lab has been supported by broad portfolio including the National Institute of Health, Crohn’s Colitis Foundation of America, Helmsley Trust, American Asthma Foundation, Rainin Foundation, Broad Medical Research Program, the Gates Foundation, the Pew Foundation and pharmaceutical companies including Genentech, Pfizer, Janssen and Boehringer-Ingelheim.
Education & Professional Highlights
Appointed
2019
Education & Fellowships
Fellowship - Washington University in St. Louis
research
St Louis,
MO
2002
Residency - Barnes Jewish Hospital
Anatomic Pathology
St. Louis,
MO
1999
Graduate School - Northwestern Univ. School of Medicine
PhD
Chicago,
IL
1995
Medical Education - Northwestern Univ. School of Medicine
Chicago,
IL
1995
Undergraduate - Northwestern University
Integrated Science Program
Evanston,
IL
1987
Additional Training
Professional Highlights
Certifications
- Pathology - Anatomic Pathology
Awards & Honors
Innovations & Patents
Memberships
Research & Publications
See publications for Thaddeus Stappenbeck, MD, PhD.
(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Industry Relationships
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.
To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.
As of 4/16/2024, Dr. Stappenbeck has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Consulting and/or Speaking. Dr. Stappenbeck receives fees of $5,000 or more per year (or, in rare cases, equity or stock options) as a paid consultant, speaker or as a member of an advisory committee for the following companies:
- Johnson & Johnson
- AbbVie, Inc.
Royalty Payments. Dr. Stappenbeck receives or has the right to receive royalty payments for inventions or discoveries commercialized through the companies shown below:
- Mobius Therapeutics, LLC
Right to Future Distribution of Cleveland Clinic Financial Interest. Dr. Stappenbeck may receive future financial benefits from the Cleveland Clinic for inventions or discoveries commercialized through the companies shown below:
- Mobius Therapeutics, LLC
Equity Dr. Stappenbeck owns stock or stock options in the following companies for activities as a founder, inventor, discover, developer:
- Mobius Therapeutics, LLC
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.
* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.
